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ABSTRACT
Purpose: To assess the feasibility of fusion imaging between intraprocedural ultrasound (US) and con-
trast-enhanced cone-beam CT (CBCT) for small (< 2 cm) hepatocellular carcinoma (HCC).
Materials and methods: Six patients (five males, one female, age range 58–80, mean 69 years), with
small (mean diameter 16.8mm) HCC poorly visible at US underwent percutaneous microwave ablation
under US/CBCT fusion guidance. During general anesthesia with apnea control, a contrast- enhanced
CBCT was acquired with an active tracker. Subsequently, real time US images were fused with CBCT
images, and treatment performed under fusion imaging guidance. Feasibility of fusion imaging and
percutaneous ablation were assessed, correct targeting (distance from center of tumor and center of
ablation area <5mm) and one-month primary technical efficacy were evaluated. Major and minor
complications as well as overall procedural time were recorded.
Results: US/CBCT fusion was feasible in all cases, allowing for completion of the treatment as previ-
ously planned (technical success 100%). Correct targeting was achieved in 4/6 cases (66%), while in
two cases, center of tumor and center of ablated area were respectively 7 and 8mm distant.
At 1month CT scan, all tumors were completely ablated (primary technical efficacy 100%). No major
or minor complications occurred. Mean overall procedure time was 127min.
Conclusions: US/CBCT fusion is a feasible technique for liver ablation, and might represent a useful
tool to increase the correct targeting of poorly US-visible HCC nodules in the angio suite.
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Image-guided ablations are currently proposed as first treat-
ment choice for small HCC [1]. Ultrasound (US) is the most
commonly-used image guidance option for percutaneous
ablations in consideration of its broad distribution, real time
capability and good general visualization of liver tumors and
normal structures. However, the technical feasibility of US-
guided ablations is often limited by poor lesion visualization,
due to lack of echogenicity difference or difficult localization
in the liver [2]. In these cases, other imaging modalities such
as computed tomography (CT), magnetic resonance (MR), or
cone beam CT (CBCT) can be used to perform liver ablations
[3]. Some techniques to improve conspicuity of target liver
lesion for percutaneous ultrasound-guided ablations have
been described, including contrast-enhanced US, and fusion
imaging of US with previously acquired CT/MR [4]. To our
knowledge, US/CBCT fusion imaging has never previously
been reported for the guidance of percutaneous ablation of
small HCC poorly visible at US. CBCT is a new advanced tool
integrated in the angiography suite: a c-arm with a flat panel
detector rotates around the patients in a time lapse that is
sufficient to ensure raw data collection; it makes 3D images
available on a selected volume usually with a relatively small
field of view (FOV). CBCT, being performed in the angio
room during the treatment, with the patient already in the
correct position, and acquired with an active tracker placed
on the patient, has the potential to provide easier fusion
with real time US imaging, and higher precision than that
obtained by pre-acquired CT or MR images. Furthermore,
application of US/CBCT fusion would allow to perform abla-
tions in the angio room without the use of the CT machine.
The aim of the present study is to describe the technique
for US/CBCT fusion imaging, and to report the preliminary
data on its technical feasibility and primary technical efficacy
as guidance in the percutaneous treatment of small HCC
poorly visible at US.
Materials and methods
Patients
Institutional Review Board approval was obtained and the
requirement for patients’ informed consent was waived due
to the retrospective nature of the study. Data of patients
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treated with US/CBCT fusion from August 2017 were retro-
spectively reviewed. In the considered period, six patients
(five males, one female age range 58–80, mean 69 years)
underwent percutaneous thermal ablation for a single HCC
<2 cm under US/CBCT fusion. All patients had a history of
HCV related cirrhosis and were selected for ablation during a
multidisciplinary board discussion in accordance to BCLC
guidelines. All six patients were previously treated for HCC:
two patients underwent laparoscopic ablations and two per-
cutaneous radiofrequency ablations elsewhere with loco
regional relapse, while the final two patients had a single
new node in the remnant liver after surgery. Four HCCs were
barely visible on US because of location in the liver dome
while two were hardly detectable at US because of a low
echogenicity difference with normal parenchyma. All HCCs
were conversely well visible at CT in the arterial (Figure 1(A))
or portal phase. At the time of treatment mean node dimen-
sion was 16.8mm (range 9–20).
Procedure
All the six procedures were performed in general anesthesia
in a sterile setting with supine decubitus and both arms gen-
tly placed above the head with dedicated soft supports. All
procedures were performed by the same interventional radi-
ologist with more than 15 years of experience.
A flat panel angiography system (Artis Zee, Siemens
Healthcare Erlangen, Germany) was used to obtain contrast
enhanced (maximum dose of 120ml, ultravist 370mg\ml and
flow rate of 3.5ml/sec) CBCT images with a 7 s c-arm rotation
time in both arterial and portal phase. A prearranged delay of
35 s from injection was established for the arterial phase and a
delay of 70 s for the portal phase. A breath-hold apnea at the
same lung expansion was performed by the anesthesiologist
during both acquisitions. A dedicated active patient tracer
(omniTRAX, CIVCO, Coralville, Iowa, US) was placed on the
upper abdomen and included in the field of view. The CBCT
acquisition parameters were: rotation angle 200 and angula-
tion step 0.5. The slice dimension was 521 512 pixels with
about 400 images per volume. The isotropic voxels had an
approximate size of 0.5mm3. The syngo X-workplace for Dyna
CT was used (Siemens Healthcare) to process images after vol-
ume acquisition and for overlapping volume images: each
CBCT volume could be fused with that previously acquired as
a further control of needle deployment and ablation area pos-
ition (Syngo InSpace 3d\3d Fusion software, Erlangen,
Germany). Mean waiting time from acquisition to image visual-
ization was about 20 s.
Fusion imaging was performed by co-registration of the
3D contrast enhanced CBCT data set with real-time ultra-
sound images. Ultrasound imaging was performed using a
dedicated ultrasound scanner configured with Volume
Navigation (LOGIQ S8 XD clear 2.0, GE Healthcare, Ill-USA)
and a C1-6 VN ultrasound transducer with electromagnetic
sensor inside. An electromagnetic transmitter is placed near
the area of interest and electromagnetic sensors are attached
to a bracket connected to the US probe and to the patient’s
active tracer. Both the transmitter and the sensors are
connected to a position sensing unit embedded in the ultra-
sound machine. The position sensing equipment allows the
ultrasound system to track the transducer’s position, and
therefore the image position, within the electromag-
netic field.
CBCT images of the arterial phase were selected for US
fusion in four nodes because of their significant contrast
enhancement (Figure 1) while the portal phase was chosen
for the last two nodes that were more evident as wash-
out areas.
Fused US was performed exactly in the same decubitus as
per CBCT, looking for a precise image matching. The same
volume apnea was required in order to completely interrupt
liver movements and under US fusion guidance, a needle
was deployed along the planned path to the target lesion.
The needle was inserted under continuous US visualization,
aiming to target the center of the lesion, as preoperatively
identified by means of US and CBCT. All the six nodes were
treated with a commonly available microwave system
(Covidien Emprint Ablation System with Thermosphere
TechnologyTM, Boulder Colorado USA). All cases were
treated with 100W power for 3min (Figure 1). At the end,
track ablation was performed. A final contrast enhanced
CBCT was carried out in order to confirm the correct tumor
ablation (Figure 2) and to exclude any complications.
Variables
The primary endpoint of the study was to verify feasibility on
US/CBCT fusion imaging. Secondary endpoints were precision
of targeting under US/CBCT fusion imaging, technical suc-
cess, primary technical efficacy and complications rate. Also,
procedural time was evaluated.
 The feasibility of fusion imaging was defined as the possi-
bility of performing fusion and real time display of
acquired CBCT images, with precise matching of the vis-
ible anatomical structures, on the judgement of
the operator.
 Correct targeting was defined as a distance from center
of tumor and center of ablation area detected at post
treatment CBCT <5mm. The distance was assessed in all
cases superimposing pre- and post-treatment CBCT
(Syngo InSpace 3d\3d Fusion software, Erlangen,
Germany) (Figure 2). Safety-free margins were also eval-
uated as adequate if 5mm [5].
 Technical success and primary technical efficacy were
defined according to the standard definition [5] and eval-
uated at immediate post-treatment CBCT and one month
CT respectively.
 Complications were defined as major and minor accord-
ing to SIR criteria [6]
 Overall procedural time was defined as the time from
anesthesia induction to the patient awakening.
 Follow-up consisted in clinical examination and a contrast
enhanced CT scan at 1 and 3 months
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Results
US/CBCT fusion was feasible in all cases, and we were able,
again in all cases, to complete the treatment as preopera-
tively planned (technical success 100%).
In four cases (66.6%), the correct targeting was confirmed
at post treatment CBCT. In two cases, the center of tumor
and center of ablated area were respectively 7 and 8mm dis-
tant. In all cases, safety-free margins were adequate.
No major or minor complications occurred.
Mean overall time from induction of general anesthesia
beginning to patient awakening was 127min. Complete
tumor ablation was achieved in all cases at one and three
months (primary technical efficacy 100%).
Discussion
Our preliminary results demonstrate that US/CBCT fusion is a
feasible technique for precisely guiding percutaneous ther-
mal ablations.
Correct targeting still remains one of the most challeng-
ing problems for percutaneous image-guided ablations.
Fusion imaging has been successfully used to improve liver
and renal lesion targeting, particularly in cases of lesions
which are poorly visible at real-time US [7–9]. However, one
of the main limits of fusion imaging is the use of CT or MRI
images acquired days before the procedure, with the patient
in a different position, and often with a different respiratory
phase. Conversely, CBCT can be performed directly in the
operating room, with the patient already in the desired pos-
ition for the procedure, and with controlled respiratory
apnea. Thus, the images obtained with CBCT performed
immediately before the ablation represent the ideal data set
for a precise matching with real-time US. CBCT has recently
been described as a useful tool for identifying liver lesions
during percutaneous thermal ablations, and it has been
applied for targeting and ablating hepatic lesions in small
cohorts of patients. In addition, CBCT has been proposed as
a possible alternative or complementary technique for
assessing ablation results [10,3]. However, several technical
aspects limit the application of CBCT as the sole method for
liver tumor ablation guidance. Motion artefacts for the slower
rotation time, patient positioning in an off-center position
and decubitus where the patient is forced to have both arms
above the head are among the main limitations of this tech-
nique [11]. In particular, the limited field of view compared
to CT might limit CBCT application especially for lesions
located in the periphery of the right liver or in severe obese
patients [11]. Our rationale for the present study was to
evaluate feasibility of US/CBCT image fusion. With the patient
already in the desired treatment position and under general
anesthesia, it would be possible to avoid the CBCT
Figure 1. (a) Small HCC node in the liver dome at baseline MDCT evident as focal contrast enhancement (red arrow). (b) US fusion with contrast enhanced CBCT:
HCC node is barely detectable with US alone but this visualisation improves due to fused CBCT node visualisation (red arrow). (c) the subsequent needle-antenna
deployment and ablation. d-1month MDCT control.
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limitations described above, such as motion artefacts due to
breath or body unintentional movement. At the same time,
the acquisition of CBCT exactly in the same position as that
employed in the US-guided procedure should ensure a bet-
ter image matching, mainly because of curarisation and a
very precise apnea control. In fact the anesthesiologist was
purposely requested to ensure that each apnea was of pre-
cisely the same volume and depth so as to ensure a stand-
ardization of diaphragmatic excursion. Furthermore, with this
setting it would be possible to perform combination therapy
of TACE and ablation at the same time, or to perform angi-
ography during the ablation.
In our series, it was always possible to achieve a correct
and precise registration of the CBCT images with real time
US images. This was also possible due to the application of
the patient active tracer that, being located on the patient at
the moment of CBCT acquisition, enabled precise and auto-
matic image coregistration. Moreover, it was also possible to
correctly target the liver tumor in 4/6 (66%) of cases, while
in two cases the center of the ablation area was slightly
more distant than 5mm from the center of the tumor. This
might be due to some degree of needle bending and organ
displacement during the procedure, which is not yet possible
to take into account with present fusion systems.
Furthermore, as this series represents our initial experience
with the method, and due to the small number of cases
included, our results should be regarded as preliminary, and
further studies are necessary to thoroughly asses the clinical
impact of this method.
Additionally, the possibility to repeat the same CBCT
acquisition with the same conditions after treatment might
be helpful to precisely assess the completeness of treatment
with adequate safety margins during the same ablative
session, and, if needed, to immediately administer a second
treatment [12]. In our series it was always possible to per-
form a final CBCT to immediately assess the result, with a
100% technical success in all cases. Again, a further contrast
enhanced CBCT evaluation at the end of the procedure is of
paramount importance to exclude early complications.
Furthermore, if bleeding should occur, treatment with
embolization can be directly performed in the same room,
with the patient still under general anesthesia. In fact, we
completely agree with Cazzato’s attitude [3] in performing
general anesthesia not only for the abovementioned tech-
nical considerations but moreover for the possibility of com-
pletely concentrating on the ongoing procedure. In our
series, no major of minor complications occurred, even
though the lesions were poorly visible at real time US and
treatments were mainly performed relying on the image
fusion guidance. In addition, the 1month CT always con-
firmed an accurate targeting of the lesion, and complete
tumor ablation, with a 100% primary technical efficacy.
Furthermore, as the role played by CBCT in interventional
oncology is increasing, in line with the current recommenda-
tions in the CIRSE/SIR protocol guidelines for selective TACE
[11], its availability in angiographic suites will probably
increase in the near future.
Some limitations of the present study must be disclosed:
firstly, this is a retrospective evaluation on a very limited
cohort of patients. Thus, our results should be regarded as
preliminary, and need confirmation in larger trials. Secondly,
precision of matching was performed on the subjective
judgement of the operator. However, the long and extensive
experience of the operator in image guided ablations, and
the confirmed correct targeting at postprocedural CBCT lend
support to the correct judgement of the operator on
Figure 2. (a) pretreatment and (b) posttreatment CBCT for a 2 cm HCC with a well-defined wash-out in portal phase. (c) pre and post treatment overlapping of
both previous CBCTs with Inspace 3d fusion software (see text). (d) centre of HCC (red cross) and (e) centre of necrosis area (white cross) evaluated on fused CBCT
images with longitudinal and transverse diameters. (f) distance between the two centre points.
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matching precision. Thirdly, results were assessed only at
short-term follow up, while for future studies, a longer obser-
vation period would be desirable.
In conclusion, US/CBCT image fusion is technically feas-
ible, and appears to be an effective image guidance modality
for achieving correct targeting and complete ablation of
small HCC which is not clearly visible at US. This method,
providing reference images acquired with the patient in the
desired position for ablation, bear the potential to overcome
the majority of the limitations of US/CT or US/MRI fusion
imaging, which are generally performed with reference
images acquired days before the procedure. Further studies
on larger series will clarify the role of this technique in the
clinical practice.
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